On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Zenosense, Inc. (ZENO) Continuous Scan Detection Technology Could Be the Most Important New Tool in the War Against MRSA

We’ve had a good run for the last seven decades or so, being able to defeat almost all microbial infections with a growing variety of powerful antibiotics, but the proliferation of antibiotics has also led to underdosing and careless prescription, directly driving the evolution of antibiotic-resistant microbes. In fact, most hospitals routinely overuse antibiotics according to recent analysis by leading healthcare providers alliance, Premier (NASDAQ:PINC), in which they reviewed data from their sizeable membership and found that the inappropriate and redundant use of combinations of the most common therapies was prevalent in almost 80% of all facilities, also amounting to $13 million a year in excess spending.

Many in the medical community are becoming increasingly alarmed by the looming threat that the evolution of multidrug resistant and now even totally drug resistant microorganisms pose. The billions per year in excess healthcare costs alone resulting from the rise of drug resistant/immune microorganisms is a serious problem, but the potential impacts to clinical patient outcomes and loss of human life, could be systemically staggering. This is especially true in highly specialized and developed economies, whose very organizational strengths make them particularly vulnerable to the kind of sporadic chaos that the rise of drug resistant/immune bacteria could create.

We are facing a possible future where such microbes, which have adapted through genetic mutation to underdosed or overused antibiotics across huge numbers of subjects, may shatter the antibiotics paradigm itself, making most, if not all of the available therapies in existence today completely useless. Compounding this problem is the growing incident rate of HAIs (hospital-acquired infections), which are conservatively estimated as affecting 5% of all patients according to the CDC’s own numbers, and which are associated with over 23k deaths per year in the U.S. alone, as well as 100k plus deaths per year worldwide.

One of the most troubling bugs in the mix is MRSA (Methicillin-resistant Staphylococcus aureus), because it is responsible for numerous infections that are difficult to treat and because it is highly resistant to the standard beta-lactam class antibiotics, including typically prescribed penicillins (even oxacillin), as well as the cephalosporin group. MRSA is of particular concern in hospitals or extended care facilities where patients who have open wounds or invasive devices, as well as patients with compromised immune systems, are at a statistically much higher risk of infection. Estimated as being responsible for around 11k deaths and 80k invasive infections in the U.S. alone each year, costing over $2.5 billion in excess healthcare costs, MRSA has been clearly identified by the CDC (alongside other drug resistant bacteria), as being a prime target for advanced detection technologies, which may be one of the only truly effective ways to curb its spread. Moreover, the ability to accurately and quickly detect sources of contamination may eventually lead to improved use of antibiotics in general, greatly reducing their application where it is unnecessary and helping to get them applied more rapidly when they are needed, ultimately helping a great deal when it comes to stemming the tide of drug resistant bacteria, directly at the source of its adaptation.

While newer technologies in use today, like the GeneXpert® system from molecular diagnostics company Cepheid (NASDAQ: CPHD), have taken MRSA detection times down from a few days to only a few hours (or even as low as 66 minutes), allowing for the reduction of costly, presumptive patient ICU isolation, as well as nursing labor, such systems still require swabbing and unit culturing. A similar approach by Switzerland-based diagnostics developer Roche (OTCMKTS: RHHBY), with their cobas® MRSA/SA Test using the cobas 4800 system, while providing highly accurate and real-time polymerase chain reaction based detection, still requires swabbing the patient and then running the vial through expensive hardware to do the detection.

This unfortunate reality is where innovative detection device development company Zenosense (OTCQB: ZENO) comes into clear and sharp focus, as they are currently co-developing a revolutionary new series of devices capable of accurately discriminating the signature VOCs (volatile organic compounds) associated with MRSA/SA, as well as lung cancer, in real-time by processing the air and the patient’s exhaled breath. Working with renowned sensor developer, Sgenia Group’s dedicated subsidiary, Zenon Biosystem, Zenosense plans to market these devices directly to hospitals and other healthcare settings where they can provide the kind of early detection needed to save huge sums of money and countless patient lives.

Such electronic nose technology is somewhat new but there have been several applications of it in recent years, including for creating sniffing devices that can detect the chemical signature of explosives. And despite existing devices, like the Airsense system installed on the ISS (international space station), being bulky and prohibitively expensive, such devices have proven to be of immense value for doing real-time detection that does not require some kind of sampling and culturing or other cumbersome test protocol.

The Zenosense device’s core technology, an algal (water) based chip under license to Zenosense from Sgenia, has already been developed and proven. Pairing this platform with a single, cheap, off-the-shelf gas sensor and the company’s own sophisticated processing software, allows the Zenosense device to achieve the same analytical capability as up to 32 sensors, which would require their own supporting processors, circuit boards, and power supplies. The result is an inexpensive and lightweight detector that can be worn or placed in a fixed position in a patient’s room, providing continuous, accurate scans that will take the guess work and hassle out of MRSA detection.

A potential game changer that could help us head off the “end of antibiotics” scenario that has the healthcare community spooked, the Zenosense MRSA/SA detection platform also has the ability to actively learn target VOC signatures across the spectrum, giving it powerful abilities that could make it a virtually indispensible feature of all healthcare facilities on earth one day.

To learn more about the company, please visit www.zenosense.net

Let us hear your thoughts: Zenosense, Inc. Message Board

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered